ResearchPad - 病例报道 https://www.researchpad.co Default RSS Feed en-us © 2020 Newgen KnowledgeWorks <![CDATA[肺癌术中并发脑梗塞1例报告]]> https://www.researchpad.co/article/5b5b8992463d7e1effa460f5 <![CDATA[手术切除巨大胸腔肿瘤1例]]> https://www.researchpad.co/article/5b5b88eb463d7e1effa460f2 <![CDATA[巨大原发性肺淋巴瘤1例并文献复习]]> https://www.researchpad.co/article/5c052ccdd5eed0c4848a8cfa <![CDATA[肺部典型类癌全身多处转移1例]]> https://www.researchpad.co/article/5c052cc6d5eed0c4848a8c3d <![CDATA[巨大纵隔原始神经外胚瘤1例并文献复习]]> https://www.researchpad.co/article/5c052c6dd5eed0c4848a8168 <![CDATA[贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾]]> https://www.researchpad.co/article/5c052c54d5eed0c4848a7ed5 本文报道1例女性肺腺癌患者,表皮生长因子受体(epidermal growth factor receptor, EGFR)、V-Ki-ras2鼠Kirsten肉瘤病毒致癌基因同源物(V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, KRAS)基因突变及棘皮动物微管相关类蛋白4与间变性淋巴瘤激酶融合基因(chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase, EML4-ALK)检测结果均为阴性;一线接受贝伐珠单抗(15 mg/kg)联合常规剂量紫杉醇、卡铂方案6周期化疗以及后续贝伐珠单抗的维持治疗。共应用贝伐珠单抗42周期,应用总剂量达44, 730 mg,患者的无进展生存期(progression-free survival, PFS)长达39个月,患者的长期生存获益远超出了不良反应所带来的危害。

]]>
<![CDATA[五次应用分子靶向药物治疗晚期肺癌患者1例]]> https://www.researchpad.co/article/5c052c52d5eed0c4848a7e99 <![CDATA[肺高分化胎儿型腺癌1例报告并14例文献复习]]> https://www.researchpad.co/article/5c052c47d5eed0c4848a7d79 <![CDATA[经左胸全隆凸切除、右主支气管切除重建术1例报道]]> https://www.researchpad.co/article/5c052c38d5eed0c4848a7c10 <![CDATA[左肺癌对侧乳腺转移男性患者1例]]> https://www.researchpad.co/article/5c052c05d5eed0c4848a7604 <![CDATA[放射性粒子植入治疗肺大细胞神经内分泌癌1例]]> https://www.researchpad.co/article/5c052b8ad5eed0c4848a65f6 <![CDATA[以肺性肥大性骨关节病为首发表现的肺癌1例报道]]> https://www.researchpad.co/article/5c052b88d5eed0c4848a65c9 <![CDATA[肺癌肉瘤1例]]> https://www.researchpad.co/article/5c052b7ed5eed0c4848a64b4 <![CDATA[右肺上叶、中纵隔并发成熟性畸胎瘤1例]]> https://www.researchpad.co/article/5c052b75d5eed0c4848a6328 <![CDATA[Combined Double Sleeve Lobectomy and Superior Vena Cava Resection for Non-small Cell Lung Cancer with Persistent Left Superior Vena Cava]]> https://www.researchpad.co/article/5c052b67d5eed0c4848a6164 A 65-year-old man with right central type of lung squamous carcinoma was admitted to our department. Bronchoscopy displayed complete obstruction of right upper lobe bronchus and infiltration of the bronchus intermedius with tumor. Chest contrast computed tomography revealed the tumor invaded right pulmonary artery, superior vena cava, and the persistant left superior vena cava flowed into the coronary sinus. The tumor was successfully removed by means of bronchial and pulmonary artery sleeve resection of the right upper and middle lobes combined with resection and reconstruction of superior vena cava (SVC) utilizing ringed polytetrafluoroethylene graft. To the best of our knowledge, this was the first report of complete resection of locally advanced lung cancer involving superior vena cava, right pulmonary artery trunk and main bronchus with persistant left superior vena cava.

]]>
<![CDATA[胸膜巨大孤立性纤维瘤合并周围型肺动脉瘤1例]]> https://www.researchpad.co/article/5c052b2ad5eed0c4848a59a2 胸膜孤立性纤维瘤,临床不多见,约占胸膜肿瘤的5%。肺动脉瘤临床亦不常见,80%位于主肺动脉,周围型较少。胸膜孤立性纤维瘤合并肺动脉瘤临床上尚未见报道。本文报道1例胸腔内巨大孤立性纤维瘤合并周围性肺动脉瘤的患者,其胸腔内的孤立性纤维瘤的生长可能加速了肺动脉瘤的形成和进展。

]]>
<![CDATA[青年肺癌左全肺术后肌肉及皮肤等全身多处转移1例]]> https://www.researchpad.co/article/5c052b1fd5eed0c4848a57e6 <![CDATA[替吉奥胶囊导致的急性间质性肺病1例报道]]> https://www.researchpad.co/article/5c052b23d5eed0c4848a586d <![CDATA[复合性小细胞肺癌伴<i>EGFR</i>基因突变1例报道及治疗体会]]> https://www.researchpad.co/article/5c052aeed5eed0c4848a50ff <![CDATA[肺腺癌靶向治疗后小细胞肺癌转化的病例报道]]> https://www.researchpad.co/article/5c052aecd5eed0c4848a50d0 近年来, 非小细胞肺癌(non-small cell lung cancer, NSCLC)静脉化疗逐渐进入平台期, 缓解率(response rate, RR)、平均总生存期(overall survival, OS)无明显改善; 随着分子生物学发展, 以表皮生长因子受体(epidermal growth factor receptor, EGFR)为靶点的EGFR酪氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitors, EGFR-TKIs)在NSCLC的治疗中疗效显著, 但患者最终均会出现耐药, 关于耐药机制目前尚未完全明确。本文详细报道1例49岁女性EGFR基因19外显子缺失突变肺腺癌患者, 在靶向治疗耐药后二次活检发现转化为小细胞肺癌(small cell lung cancer, SCLC), 予以SCLC化疗方案两周期有效; 通过分析患者诊疗过程、疗效, 对相关机制进展作一综述。

]]>